FindTrial
Sign In

Resolute Onyx

DEVICE4 trials

Sponsors

Thorax Centrum Twente, Seoul National University Hospital, University of Padova, Elixir Medical Corporation

Conditions

Acute Coronary SyndromeAngina PectorisCoronary Artery DiseaseCoronary RestenosisCoronary StenosisIschemic Heart DiseaseMyocardial InfarctionUnstable Angina Pectoris

Unknown Phase

Bioresorbable Polymer ORSIRO Versus Durable Polymer RESOLUTE ONYX Stents
NCT02508714
Thorax Centrum TwenteAcute Coronary Syndrome, Angina Pectoris, Coronary Artery Disease +3
Start: 2016-10-07End: 2019-03-31Updated: 2017-02-03
Effect and Efficacy of Onyx™, Zotarolimus-eluting Stent for Coronary Atherosclerosis
NCT03151018
Seoul National University HospitalAcute Coronary Syndrome, Angina Pectoris, Coronary Artery Disease +1
Start: 2015-05-31End: 2021-05-31Target: 4000Updated: 2017-05-12
The Rolex Registry (Revascularization Of LEft Main With Resolute onyX)
SuspendedNCT03316833
University of PadovaCoronary Artery Disease
Start: 2017-11-01End: 2025-12-31Updated: 2023-01-31
Infinity-Swedeheart Registry Based Randomized Clinical Trial (R-RCT)
Active, not recruitingNCT04562805
Elixir Medical CorporationCoronary Artery Disease, Ischemic Heart Disease
Start: 2020-09-30End: 2028-07-31Target: 2400Updated: 2024-10-16

Related Papers

Impact of diabetes on three-year outcome after coronary stenting in patients with polyvascular atherosclerotic disease - a secondary analysis of the randomized TWENTE trials.
2025-07-061 citations
Elderly patients treated with Onyx versus Orsiro drug-eluting coronary stents in a randomized clinical trial with long-term follow-up.
2025-03-04
Clinical outcome after bleeding events following coronary stenting in patients with and without comorbid peripheral arterial disease
Cardiovascular Intervention and Therapeutics2024-12-195 citations
Bioadaptor implant versus contemporary drug-eluting stent in percutaneous coronary interventions in Sweden (INFINITY-SWEDEHEART): a single-blind, non-inferiority, registry-based, randomised controlled trial.
2024-10-2815 citations
Percutaneous Coronary Intervention Using the DynamX Sirolimus‐Eluting Bioadaptor: 12‐Month Clinical and Imaging Outcomes
Journal of Interventional Cardiology2024-01-011 citations
Premature coronary artery disease in all-comers undergoing first PCI
European Heart Journal2023-11-01
First myocardial infarction in patients with premature coronary artery disease: insights into patient characteristics and outcome after treatment with contemporary stents
European Heart Journal Acute Cardiovascular Care2023-08-224 citations
Outcome of percutaneous coronary intervention using ultrathin-strut biodegradable polymer sirolimus-eluting versus thin-strut durable polymer zotarolimus-eluting stents in patients with comorbid peripheral arterial disease: a post-hoc analysis from two randomized trials
Cardiovascular Diagnosis and Therapy2023-08-012 citations
Impact of premature coronary artery disease on adverse event risk following first percutaneous coronary intervention
Frontiers in Cardiovascular Medicine2023-06-195 citations
A large, prospective, multicentre study of left main PCI using a latest-generation zotarolimus-eluting stent: the ROLEX study.
2023-02-0614 citations
Clinical outcome up to 2 years after percutaneous coronary intervention in all-comers with concomitant symptomatic peripheral arterial disease: a pooled analysis in 9,204 randomized trial participants
European Heart Journal2022-10-01
Impact of prediabetes and diabetes on 3-year outcome of patients treated with new-generation drug-eluting stents in two large-scale randomized clinical trials
Cardiovascular Diabetology2021-10-3026 citations
First Report of 3-Year Clinical Outcome After Treatment With Novel Resolute Onyx Stents in the Randomized BIONYX Trial.
2021-07-1319 citations
Acute myocardial infarction treated with novel Resolute Onyx and Orsiro stents in the randomized BIONYX trial
Catheterization and Cardiovascular Interventions2021-03-105 citations
Diabetic patients treated with novel thin composite-wire strut zotarolimus-eluting stents versus ultrathin strut sirolimus-eluting stents in the BIONYX trial: 2-year results of a prespecified analysis
European Heart Journal2020-11-01
Thin Composite-Wire-Strut Zotarolimus-Eluting Stents Versus Ultrathin-Strut Sirolimus-Eluting Stents in BIONYX at 2 Years.
2020-05-0130 citations
Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt-chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomised non-inferiority trial.
2018-09-22110 citations
Bioresorbable Polymer-Coated Orsiro Versus Durable Polymer-Coated Resolute Onyx Stents (BIONYX): Rationale and design of the randomized TWENTE IV multicenter trial.
2017-12-217 citations